Etrolizumab, a monoclonal antibody against the β7 integrin subunit, has been found effective in ulcerative colitis. Now, a retrospective analysis of data from 110 patients with ulcerative colitis in a phase II placebo-controlled trial of etrolizumab and 21 patients who did not receive the drug or did not have IBD, reports that patients expressing high levels of granzyme A or integrin alpha E mRNA benefit most from etrolizumab. A reduction in T-cell activation and inflammatory cytokines seems to be involved.
References
Tew, G. W. et al. Association between response to etrolizumab and expression of integrin alpha E and granzyme A in colon biopsies of patients with ulcerative colitis. Gastroenterology 10.1053/j.gastro.2015.10.041
Rights and permissions
About this article
Cite this article
Who benefits the most from etrolizumab in ulcerative colitis?. Nat Rev Gastroenterol Hepatol 12, 670 (2015). https://doi.org/10.1038/nrgastro.2015.197
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2015.197
